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Abstract: Translationally controlled tumor protein (TCTP), also called histamine releasing factor
(HRF) or fortilin, is a multifunctional protein present in almost all eukaryotic organisms. TCTP is
involved in a range of basic cell biological processes, such as promotion of growth and development,
or cellular defense in response to biological stresses. Cellular TCTP levels are highly regulated in
response to a variety of physiological signals, and regulatory mechanism at various levels have been
elucidated. Given the importance of TCTP in maintaining cellular homeostasis, it is not surprising
that dysregulation of this protein is associated with a range of disease processes. Here, we review
recent progress that has been made in the characterisation of the basic biological functions of TCTP,
in the description of mechanisms involved in regulating its cellular levels and in the understanding
of dysregulation of TCTP, as it occurs in disease processes such as cancer.
Keywords: TCTP (HRF; fortilin); growth and development; biological stress reactions; autophagy;
regulation of protein synthesis; regulated protein degradation; cancer; cardiovascular diseases

1. General Overview
TCTP (also referred to as: HRF, fortilin, P23; gene symbol tpt-1; in yeast: TMA19 or Mmi1) was
first described almost 40 years ago as a growth factor-induced, translationally controlled protein in
murine cell lines [1,2]. The elucidation of its biological importance was initially hampered by the fact
that, based on its amino acid sequence, it is not related to any other known protein family. It took
a considerable international research effort, spread over more than three decades, to piece together
the puzzle and reveal our current picture of the biological function of TCTP and of its involvement
in various diseases. Several review articles on TCTP/HRF/fortilin have been published previously,
and the first ‘TCTP book’ appeared in 2017, a compilation of 16 individual review articles covering a
wide range of topics relating to this multifunctional protein [3]. Since then, a considerable number of
new papers reported various novel aspects on TCTP, and it is the aim of this review to summarise
these more recent additions to the ‘TCTP story’. Being part of the Special Issue ‘Role of TCTP in Cell
Biological and Disease Processes’ in Cells, our review will only briefly touch on those topics that are
the subject of the other review articles within this Special Issue. However, we will discuss the research
papers of the Special Issue, where appropriate, to put these into context.
2. Importance of TCTP in Core Cell Biological and Stress Reactions
The involvement of TCTP in a multitude of cell biological processes is reflected by the large number
of interacting proteins. Compilations of the many interaction partners of TCTP have been published in
the above-mentioned book [4–6]. A more recent study, using current proteomics approaches combined
with in silico network and gene ontology enrichment analysis, identified 113 interacting proteins [7],
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which were allocated to the following gene network clusters: translation, stress response, cytoskeleton,
signal transduction, proteasomes, nucleosomes and transcription, RNA binding and metabolic enzymes.
These clusters can be roughly associated with the following three core biological processes. We will
discuss recent advances on the participation of TCTP in these processes, as summarised in Table 1 below.
2.1. Growth and Developmental Processes
There is a considerable body of evidence for the involvement of TCTP in cell and organ growth,
as well as in developmental processes, most aspects of which were reviewed in the following chapters
of the ‘TCTP book’: cell cycle progression [5,8], early development [5,9], and organ growth and
development [9–11]. Since then, several new studies have extended our insight into potential
mechanisms, through which TCTP might participate in these processes.
Regarding cell cycle regulation in early development, Jeon et al. showed that TCTP regulates
spindle assembly during postovulatory aging of mouse oocytes, thereby preventing deterioration
of oocyte quality [12]. The targeting of yet another mechanism for cell cycle control by TCTP was
revealed in a more recent paper [13]. The authors showed that TCTP interacts with CSN4, a subunit of
the COP9 signalosome complex, which controls the G1/S transition of the cell cycle through regulating
Cullin–Ring ubiquitin ligases. This mechanism is conserved between plants (Arabidopsis) and insects
(Drosophila). The latter observation is consistent with another report showing that disruption of TCTP
using CRISPR/Cas9 in the silkworm Bombyx mori resulted in developmental arrest and in subsequent
lethality in the third instar larvae, caused by defects in proliferation of intestinal epithelial cells [14].
Similarly, a recent report demonstrated the importance of TCTP in stem cells of the midgut in Drosophila
for tissue homeostasis and regeneration [15]. As potential mechanisms, the authors suggest the
regulation of protein synthesis by TCTP (Section 2.2. below) and crosstalk with two important growth
regulating signalling pathways.
The importance of TCTP for organ development was supported by a new report showing that
TCTP promotes liver regeneration via mTORC2/Akt signalling [16], by studies on axon guidance [17–19]
and on brain development [20]. Roque et al. demonstrated the role of TCTP for axon guidance and
development in the visual system of Xenopus laevis [18] and the importance of its localised translational
regulation in axonal growth cones [17]. A recent paper confirmed the importance of TCTP for general
brain development in mice [20]. Conditional TCTP-knockout mice displayed retardation in brain
development and died at the perinatal stage. An interesting case of the involvement of TCTP in organ
development was reported for plants [21]. The authors demonstrated that in Arabidopsis thaliana,
the mRNA (and protein) of the AtTCTP1 protein is transported over a long distance from scions into the
roots, where it provides a signal to govern the formation of lateral roots. In contrast, the ‘endogenous’
AtTCTP1, locally produced in the root cells, drives the elongation of the roots. Thus, TCTP is a molecule
crucial for establishing the root architecture of plants.
2.2. Regulation of Protein Synthesis and Degradation
At the beginning of this century, the association of TCTP with ribosomes [22] and the translational
machinery [23] was identified in yeast. A more specific study demonstrated the interaction of
TCTP with translation elongation factor eEF1A and its guanine nucleotide exchange factor (GEF),
eEF1B [24]. Subsequently, the interaction of TCTP with elongation factors of the EF1 family and with
other components of the translational apparatus was confirmed both in human cells [7,25] and in
Drosophila [15]. Consistent with this is the observation that the genes of ribosomal proteins, elongation
factors, and of TCTP all belong to the class of ‘TOP genes’, whose mRNAs have a common signature,
the 50 -terminal oligo-pyrimidine tract (50 -TOP) [26], and are therefore translationally regulated [27].
Later, the interaction of TCTP with eEF1B was studied in more detail, using a range of structural
methods [28]. This paper demonstrated that TCTP binds to the central acidic region of eEF1B and
that in both these proteins the mutually interacting regions are highly conserved in evolution, thus
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representing the most conserved interaction of TCTP. This conclusion was also supported by the
recently published solution structure of TCTP from a unicellular micro-alga [29].
The functional importance of TCTP in its interaction with translation elongation factor 1 and/or
its GEFs still needs to be fully clarified. The initial observation was that, through binding to eEF1Bbeta,
TCTP impaired the GDP-GTP exchange reaction on eEF1A, stabilising it in its GDP-bound form [24].
A variation of this mechanism was proposed very recently by a Japanese group interested in mechanisms
involved in formation of neurofibromatosis type 1 (NF1)-associated tumors. Their work confirmed
the interaction of TCTP with EF1A, as well as with its GEF complex consisting of EF1B, EF1G, and
EF1D [7]. In addition, this paper showed that the interaction of TCTP with EF1A2, an isoform of EF1A
preferentially expressed in neuronal tissue and skeletal muscle, is much stronger compared to that
with the normal isoform, EF1A1. The authors concluded that, in NF1-associated tumor cells, TCTP
binds to the GDP-bound form of EF1A2, thus preventing its dimerisation and inactivation. In this
way, TCTP facilitates the binding of the GEF complex to GDP-bound EF1A2, promoting the GDP-GTP
exchange reaction and recycling of EF1A2 [7].
Whether the net effect of TCTP on translation elongation is positive [7] or negative [24], both should
result in a general regulation of protein synthesis. However, another well-documented example of
translational control that targets the elongation cycle of protein synthesis has been shown to result in a
selective translational advantage for specific mRNAs. Elongation factor 2 (EF2)-kinase phosphorylates
EF2, thereby slowing down protein synthesis. This results in an increased expression of proteins
implicated in cell migration and cancer cell metastasis [30]. It remains to be seen whether the effect of
TCTP on EF1 activity may also lead to a preferential translation of certain mRNAs.
Two additional observations confirm the involvement of TCTP in the translational machinery, i.e.,
the recently reported interaction of TCTP with the receptor of activated protein kinase C (RACK1) [31]
and the identification of TCTP as an mRNA-binding protein in HeLa cells (Supplementary Table S1
in [32]). These two observations may be related to each other, since RACK1 was identified as a
ribosomal protein that is located close to the ribosomal mRNA entry site [33]. RACK1 serves as a
ribosomal scaffolding protein that is involved in targeting the ribosome to various signalling modules
and also to specific subcellular locations, such as focal adhesion sites [33].
Several examples of an involvement of TCTP in the regulated degradation of specific proteins
have been reported. A review on this topic was published in the TCTP book [34]; here we will briefly
summarise the relevant examples (see also Table 1 below):
1. TCTP stabilises the following client proteins by masking their ubiquitination sites, thereby
preventing their proteasomal degradation. These are the anti-apoptotic protein Mcl-1 [35], the protein
kinase Pim-3, a proto-oncogene [36], the antioxidant enzyme peroxiredoxin PRX1 [37], and the tobacco
histidine kinase 1, NTHK1 [38]. This kinase represents the receptor for the phytohormone ethylene
in plants. In this way, TCTP reduces the plant response to ethylene, which enhances plant growth
and cell proliferation [38]. A specific case is the stabilisation of hypoxia-inducible factor HIF1α, where
TCTP does not bind to HIF1α itself, but to the von-Hippel-Landau protein (VHL), which normally acts
as E3-ligase for HIF1α. TCTP binding results in ubiquitination of VHL and in its own proteasomal
degradation, preventing the degradation of HIF1α [39].
2. For other proteins, TCTP actively promotes degradation. For example, to induce degradation
of the tumor suppressor protein p53, TCTP binds to p53-MDM2 complexes and inhibits MDM2
auto-ubiquitination, resulting in MDM2-mediated ubiquitination and degradation of p53 [40]. TCTP
also promotes the degradation of cell cycle protein phosphatase Cdc25, which is important for an
orderly mitotic exit. TCTP overexpression, as it occurs in hepatocellular carcinoma (HCC), induces
ubiquitination and degradation of Cdc25, eventually resulting in chromosome missegregation [41].
3. Apart from regulating the degradation of specific proteins, in yeast, TCTP (TMA19; Mmi1)
has also been shown to interact with proteasomal proteins [42] and to colocalise with the proteasome
under heat stress conditions [43]. Yeast Mmi1 slightly inhibited proteasome activity, and was found to
colocalise with two proteins of a de-ubiquitination complex in heat-stressed cells [43].
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2.3. Biological Stress Reactions and Autophagy
The role of TCTP as an anti-apoptotic protein involved in protecting cells in a range of stress
conditions (inclusive of DNA damage [44]) in mammalian cells [5,45], in plants [9], and in insects [10]
has been reviewed in several articles of the TCTP book [3]. Here, we will just summarise the more
recent contributions in this area.
Two recent papers demonstrated the importance of TCTP as a survival factor in mammalian
organs. Cai et al. showed that TCTP plays a critical role for the survival of cardiomyocytes and has a
protective function against drug-induced cardiac dysfunction in mice [46]. Another paper, published in
this Special Issue in Cells, studied the importance of TCTP for the development of the central nervous
system [20]. The authors generated mice that are disrupted in TCTP expression in neuronal and glial
progenitor cells. These mice die at the perinatal stage, and they show slight abnormalities in early
brain development that are associated with increased apoptosis, demonstrating that TCTP is a critical
protein for cell survival during early neuronal and glial differentiation.
It was well established for quite some time that TCTP is involved in protecting cells in a wide
range of stress conditions. However, up until recently, it was not known that it also plays a role in the
ER-stress defense program, the unfolded protein response (UPR). This gap has been closed by a recent
paper by Pinkaew et al. [47]. IRE1α is one of three main players in initiating the UPR; it has protein
kinase and endonuclease activity and is ultimately responsible for the induction of apoptosis, once the
protein overload in the ER becomes overwhelming. The authors showed that TCTP (fortilin) is able to
bind to phosphorylated IRE1α, thereby preventing the activation of the JNK apoptosis pathway by
IRE1α.
The importance of TCTP in biological stress reactions was also demonstrated in non-mammalian
systems. De Carvalho et al. overexpressed TCTP from tomatoes in tobacco plants, which resulted in
an increased growth rate and an improved performance under salt and osmotic stress conditions [48].
The transgenic plants displayed an increased expression of genes involved in photosynthesis, fatty
acid metabolism, and water transport, and this was paralleled by an increased photosynthetic rate.
On the other hand, genes involved in ethylene biosynthesis (a plant hormone) were down-regulated
by TCTP overexpression. This is consistent with the observation that TCTP binds to the ethylene
receptor in tobacco plants and reduces its response to ethylene [38]. Studying the role of TCTP in
Trypanosomes, Jojic and co-workers reported that, in the bloodstream form of the parasite, depletion of
TCTP expression resulted in a reduced growth rate and also in a slower recovery after heat stress [49].
The importance of TCTP in the development of resistance against the insecticide deltamethrin was
investigated in Drosophila kc cells [50]. RNAi-knockdown and overexpression experiments confirmed
that TCTP partially protects these cells against deltamethrin-induced cell death.
Over the past decade, autophagy has been recognised as a central biological process, essential for
maintaining cellular homeostasis; but the involvement of TCTP in this pathway has only recently been
investigated. In the ‘TCTP book’, this aspect of TCTP function has only briefly been touched on in two
articles [5,34] and also here, we will not cover it in much detail, since another review article in this
Special Issue discussed the role of TCTP and autophagy in relation to tumorigenesis [51].
So far, the effect of TCTP on autophagy has only been studied in three original reports (Table 1),
with partially conflicting results. The earliest of these papers found that TCTP is one of five genes
upregulated by artificial selection in the ovaries of domesticated vs. wild pigs [52]. The authors also
observed that TCTP is located in the cytoplasm, in a pattern similar to the autophagy protein LC3.
In COS-7 cells kept under normoxic conditions, TCTP knockdown resulted in enhanced AMPK activity
and an increase in the levels of the LC3-II protein, whereas the opposite was true under hypoxic
conditions. The observed effects could be reversed by re-introducing the TCTP gene into the cells via a
lentivirus construct. TCTP was also found to interact with the ATG16 complex of autophagic proteins.
The authors concluded that TCTP positively regulates autophagy via the AMPK/mTORC1 pathway.
Another, more recent paper arrived at a different conclusion i.e., that in HeLa cells, TCTP inhibits
autophagy through two separate pathways, 1. the AMPK/mTORC1 signalling pathway by inhibiting
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AMPK and activating mTORC1, and 2. through activation of Bcl-2, which in turn leads to an inhibition
of the formation of the autophagic Beclin1 complex [53]. Both these studies demonstrated that TCTP is
indeed able to modulate autophagy, however, the actual outcome is very much dependent on the precise
cell physiologic conditions. Consistent with this, another paper on TCTP regulation of autophagy,
published in this Special Issue, observed that TCTP negatively affects rapamycin-induced autophagy
in the post-diauxic growth phase in yeast, but not autophagy induced by nitrogen starvation [54].
Table 1. The importance of TCTP in basic biological processes.
Process

Examples

Potential Mechanism

References

Cell growth
and organ
development

Prevention of oocyte aging
Cell cycle progression
Insect development
Tissue regeneration
Brain development
Branching of plant roots

Regulates spindle assembly
Signalosome interaction
Proliferation of epithelial cells
Stem cells; protein synthesis
(Axon guidance)
Initiation of lateral roots

[12]
[13]
[14]
[15,16]
[18–20]
[21]

Regulation
of protein
synthesis

Association with proteins
of the translational apparatus
- TCTP binding to EF1B
- TCTP binding to EF1A2
- Interaction with RACK1
- Binding to mRNAs

(in yeast)
(in human cells and Drosophila)
Regulation of the GEF activity
of EF1B on EF1A
(Part of the mRNA interactome)

[22,23]
[7,15]
[24,25,28]
[7]
[31]
[32]

Regulation
of protein
degradation

Stabilisation of: HIF1α,
Mcl-1, PIM-3, PRX1, NTHK1
Destabilisation of p53, Cdc25
Binding to proteasomes

Prevention of
ubiquitination
Induction of ubiquitination
Inhibition of proteasomes

[34,39]
[35–38]
[40,41]
[42,43]

Biological
stress
responses

Cardiomyocyte protection
ER stress; (binding to IRE1α)
Osmotic stress in plants
Heat stress in Trypanosomes

Blocking apoptosis by Bnip3
Blocking apoptosis by JNK
Increases photosynthesis

[46]
[47]
[48]
[49]

Autophagy

Stimulation of autophagy
Reduction of autophagy
Reduction of autophagy

AMPK/mTORC1 pathway
AMPK pathway; Beclin1
Rapamycin-induced autophagy

[52]
[53]
[54]

2.4. Extracellular Functions of TCTP(HRF)
Since the discovery of the histamine releasing factor (HRF) activity of TCTP in 1995 [55], it is
established that, apart from its many intracellular functions, TCTP also acts as an extracellular molecule,
typically in the context of immune reactions associated with allergic diseases. However, we will not
expand on this, since the review by Kawakami et al. in this Special Issue [56] provided an up-to-date
account on HRF and the current understanding of its involvement in various disease settings and its
potential as a new therapeutic target. For a historic overview on the ‘HRF story’, the reader is referred
to an earlier review article by Susan MacDonald [57].
3. Mechanisms of Regulation of Cellular TCTP Protein Levels
Being an anti-apoptotic protein involved in cellular stress responses, it is not surprising that
the levels of TCTP are highly regulated. In our previous review article [5], we compiled a list of
cell physiologic conditions that resulted in alterations of cellular TCTP levels. We also provided an
overview on the principal mechanisms involved in TCTP regulation. As the name of the protein
suggests, translational regulation plays an important role among these processes; it represents the
most effective means for rapid de novo-synthesis. However, other modes of protein regulation, such as
transcriptional control or regulated protein degradation, are also involved (Table 2, below). Since
the publication of our review article [5], several new examples and mechanisms of regulation of
TCTP levels have been revealed, and here we will largely focus on these more recent developments in
this area.
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3.1. Transcriptional Regulation
To date, numerous instances of transcriptional regulation of TCTP synthesis have been reported [5],
but precise mechanistic investigations were only performed in a few cases. Thiele and coworkers
demonstrated that TCTP synthesis is induced by phorbolester (PMA) through the cAMP-PKA signalling
pathway and activation of transcription factor CREB [58]. They also studied the regulation of TCTP
expression under stress conditions, such as heavy metals, and showed that copper induced TCTP
synthesis at both the transcriptional and the translational level [59]. Several similar studies showed
that TCTP is transcriptionally regulated under a variety of stress conditions [5].
Of particular relevance for cancer research was the demonstration that the tumor suppressor
protein p53, acting as a transcription factor, negatively affects TCTP expression [40]. Since p53
is frequently mutated in cancers, this contributes to the observed deregulation of TCTP synthesis
in cancers. A more recent paper reported another example of transcriptional regulation of TCTP
expression [31]. The authors studied a specific transcription factor, insulin-response element binding
protein 1 (IRE-BP1), whose decreased expression in insulin target tissues contributes to the development
of insulin-resistant diabetes in rats. Normally, insulin-induced PI3K signalling results in the proteolytic
cleavage of IRE-BP1 and release of the active C-terminal fragment of the protein. In order to study the
target genes of IRE-BP1, the investigators analysed the proteome of pancreatic islets from transgenic
mice overexpressing the active fragment of IRE-BP1, compared to the corresponding proteome from
control mice. The overexpression of two of the identified target genes of IRE-BP1 in the transgenic mice
was further confirmed by Western blotting, specifically the genes for RACK1 and for TCTP. Moreover,
the authors discovered the interaction of RACK1 with TCTP by Co-IP experiments [31].
3.2. Translational Regulation
TCTP was originally discovered by the fact that its synthesis is induced after serum-stimulation of
murine cells by translational activation of its preformed mRNA [1]. By 2016, several additional examples
of translational regulation of TCTP synthesis were reported (reviewed in [5]), and among these, two
principal translational control mechanism were found to be involved: (1) the growth factor-related
induction of TCTP synthesis via the mTORC1-eIF4E signalling pathway [60,61], and (2) the negative
regulation of TCTP synthesis via activation of PKR and eIF2α-phosphorylation. The latter occurs under
serum-starvation [62] and also under Ca2+ -stress conditions [63]. Our original observation that TCTP
mRNA is a highly structured molecule that binds to and activates PKR [62] was further confirmed
by a recent structural analysis of this mRNA under a various conditions, inclusive of the influence of
riboSNitches [64].
Similarly, the regulation of TCTP synthesis through mTORC1 was recently observed in a very
specific biological system, the retinal axon. Based on the findings from genome-wide screens, that
TCTP mRNA is one of the most abundant mRNAs localised in the growth cone of axons, Roque et
al. studied the role of TCTP in the development of the retinal axon in Xenopus laevis. They showed
that it is indeed a protein essential for the normal development of the visual circuitry in the frog [18].
In a follow-up paper, the authors specifically investigated the translational regulation of TCTP and
its importance for axon guidance [17]. They demonstrated that in axons of retinal ganglion cells,
local TCTP synthesis is regulated by two axon guidance cues in an mTORC1-dependent fashion.
In a completely different biological system, the intestinal stem cells in the midgut of Drosophila,
yet another example of posttranscriptional regulation of TCTP synthesis was observed [15]. In this
case, the Hippo signalling pathway has been implicated. However, the precise mechanism still awaits
further characterisation.
The two translational control mechanisms referred to so far that target TCTP mRNA, act on the
50 -TOP (the mTORC1 signalling pathway), or on the highly structured area of the mRNA (for PKR
activation). The latter most likely comprises the CG-rich 50 -UTR and a 50 -terminal stretch of the coding
region [64]. Other translational control modes, targeting the 30 -UTR of TCTP mRNA, emerged only
recently. This is surprising, since for 20 years, we have known that in many organisms, TCTP mRNA
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occurs in two isoforms, which differ in the length of their 30 -UTRs [65], with the shorter isoform usually
being the most abundant one. Therefore, the biological importance of the second isoform is still elusive.
In addition, for the regulation of TCTP expression in the axonal growth cone, it was shown that it is
the shorter isoform, which is subject to translational regulation [17]. The first example of regulation of
TCTP expression via the 30 -UTR of its mRNA was revealed in a recent, very interesting report [66].
The authors studied the expression of TCTP in Trypanosoma brucei and found that this unicellular
parasite during its life cycle differentially expresses two TCTP paralogs, TCTP1 in the procyclic life
form (in the tsetse fly) and TCTP2 in the blood stream form in humans. The two mRNAs largely differ
in their 30 -UTRs, with TCTP2-mRNA bearing a 1.5-fold longer one. The authors demonstrated that
the 30 -UTRs confer differential stability to these TCTP mRNA isoforms and that, for TCTP2 mRNA,
the cis-acting element largely resides in the first 160 nucleotides of the 30 -UTR. However, the precise
characterisation of the cis-acting element awaits further investigation.
Table 2. Mechanisms involved in regulating cellular TCTP levels.
Type of Regulation

Example

Mechanism Involved

References

Transcriptional
regulation

Induction by PMA
Copper stress reaction
Tumor suppressor p53
Insulin response

Transcription factor CREB
Transcription and Translation
Inhibition of tpt1 transcription
Transcription factor IRE-BP1

[58]
[59]
[40]
[31]

Translational
regulation

Induction of TCTP synthesis
- by growth stimuli
- during axon guidance

via mTORC1-eIF4E signalling
- in muscle
- in retinal ganglion cells

[60]
[61]
[17]

Negative regulation
in cell stress responses

Activation of PKR and
phosphorylation of eIF2α

[62–64]

Developmental regulation
in Trypanosomes

mRNA stability regulation
via the 30 -UTR

[66]

Regulation by micro-RNAs
- in various cancers

miR-130a
miR-27b; miR-145-5p; miR-125-3p

[67]
[68–70]

Stabilisation of TCTP

- by Mcl-1
- by Hsp27 (in prostate cancer)
Ubiquitin/proteasome pathway
Ubiquitin/proteasome pathway
Lysosomal degradation

[71]
[72,73]
[74]
[75]
[76]

Regulation
of protein
degradation

DHA destabilises TCTP
Partial degradation in mitosis
Chaperone-mediated autophagy

Another mode of posttranscriptional regulation that targets individual mRNAs, typically via their
is the regulation by micro-RNAs. These short RNA molecules recruit ‘their’ target mRNAs to
the RNA-induced silencing complex (RISC), which leads to translational arrest or even degradation
of the mRNA. However, information about validated cases of TCTP mRNAs being regulated in this
way is scarce (Table 2). In 2012, two papers reported that TCTP mRNA is regulated by miRNAs, i.e.,
miR-130a [67] and miR-27b [68], respectively. In the latter case, the authors observed that miR-27b
levels were significantly reduced in tumor tissue of oral cancer patients, resulting in an increase of
TCTP protein expression. Similarly, two recent papers reported on the deregulated TCTP expression in
cancer, due to low levels of certain miRNAs, i.e., miR-145-5p in prolactinoma [69] and miR-125-3p in
lung cancer [70]. In the latter paper, the authors studied the induction of TCTP in lung cells by tobacco
smoke carcinogens. They found that miR-125-3p, is able to prevent the expression of a TCTP 30 -UTR
reporter gene construct and that this miRNA is significantly down-regulated in xenografts generated
from cells pretreated with these carcinogens.
30 -UTRs,

3.3. Regulation of Protein Degradation
The mechanisms of regulated degradation of the TCTP protein were reviewed in detail in [34]
and were also covered in a review article in this Special Issue in Cells [51]. Here, we will just briefly
summarise the few cases known today (Table 2). Earlier papers reported the stabilisation of the TCTP
(fortilin) protein by the anti-apoptotic protein Mcl-1 [71] and by the small heat shock protein Hsp27 [72],
thereby preventing TCTP degradation in specific conditions, such as prostate cancer [73]. It was also
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shown that the antimalarial drug dihydroartemisinin (DHA), which is also used as an anti-cancer agent,
binds TCTP and targets it for the ubiquitin-proteasome degradation pathway [74]. Another paper
reported at the same time that, during mitosis and during meiotic exit, TCTP is partially degraded [75].
Our recent study characterised the pathway for specific TCTP degradation as acetylation-dependent
chaperone-mediated autophagy (CMA), which eventually leads to lysosomal degradation of the protein
and involves the proteins Hsc70 and LAMP-2A [76].
4. Disease Processes Involving Dysregulation of TCTP
4.1. Mechanisms of Cancer Promotion by TCTP
When we initially discovered that TCTP was overexpressed in a majority of tumors [77],
it became clear that its inhibition could potentially result in decreased tumorigenicity.
This reprogramming/reversion of cancer cells was found in breast tumor cells, lung cancer, colon
carcinoma, and melanoma [77–79]. Typically, decreasing TCTP levels led to a restructuring of the
tumor architecture, where breast cancer cells formed again ductal-like structures, reminiscent of normal
tissues [77]. This suggested that TCTP regulates a series of oncogenic and tumor suppressor pathways
and that its silencing suppresses malignant growth [79]. These aspects of TCTP have been extensively
reviewed previously [78]. Since then, it has been confirmed that TCTP is overexpressed in most tumors
including clinical samples [5]. The mechanistic way, through which TCTP exerts its action, is most
probably by interacting with hundreds of proteins, influencing their function, in different ways [78,80].
As TCTP is a highly conserved protein expressed in all eukaryotic organisms, some of the crucial
knowledge has been generated through work in Drosophila by K.W. Choi and colleagues. They found
that TCTP regulates the TOR pathway through interaction with the dRheb GTPase [81]. Reduction of
TCTP levels led to a reduced cell number, along with a smaller organ size. Given the importance of the
mTOR pathway in cancer, these results provided one of the links between TCTP and tumorigenicity.
These findings in Drosophila were further extended by showing the implication of 14-3-3 proteins;
their interaction with TCTP and Rheb is necessary for the regulation of TOR [82]. The same group
demonstrated that TCTP also regulates genome stability through modulation of dATM, one of the
molecular complexes implicated in the DNA damage response [83]. In addition, they showed that
TCTP binds to Brahma and negatively regulates its activity [84]. Brahma is the catalytic subunit of the
SW1/SNF complex, which modulates chromatin and DNA repair, and which is mutated in more than
20% of human cancers [85]. In an elegant study from Azzam’s group [86], it was shown that TCTP
forms complexes with ATM and γ-H2AX, suggesting a role in DNA damage and repair following
exposure of human cells to low-dose γ-rays. Altogether, these data provide genetic evidence in support
of the interaction of TCTP with the TOR-dependent oncogenic pathway, and of its role in maintaining
genome stability.
Several studies link TCTP to epithelial to mesenchymal transition (EMT). This biological process
is fundamental in early stages of embryonic development, such as the formation of the body plan
during gastrulation [87]. Significant knowledge has been generated on the regulation of EMT in
different developmental contexts, and evidence for its implication in cancer and metastasis is rapidly
progressing [87], but still awaiting confirmation by clinical data. There has also been substantial
progress in deciphering the molecular pathways involved in EMT and cancer [87]. The plasticity
of cancer cells is key in EMT, especially in reprogramming somatic cells to ‘stemness’. Since TCTP
plays an important role in tumor reprogramming, it was speculated that it might be part of the
EMT induction process. In an interesting study [88], LLC-PK1 kidney epithelial cells were used
to test in vitro the potential role of TCTP for the regulation of EMT. The overexpression of TCTP
enhanced migration with a reduced expression of E-cadherin and increased expression of transcription
factors repressing E-cadherin, such as ZEB1, slug, or twist. Depletion of TCTP reversed the EMT
phenotype and suppressed migration. Results suggested that TCTP acts through metalloproteinases,
specifically MMP-9, to facilitate cell invasion [88]. In addition, the study provided data indicating
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that TCTP regulates pulmonary metastasis of melanoma. Another study [89], this time using A549
lung adenocarcinoma cells, suggested that TCTP was a target of TGF-β1 and necessary for EMT and
cytoskeleton reorganisation. Using the same cell line, it was further confirmed that TCTP promotes
EMT and tumorigenicity [90,91] by influencing the expression levels of key transcription factors (ZEB1
and alpha SMA), and of miR-200a, miR-141, and miR-424 [90]. A very recent study also showed that
TCTP is a key mediator in the induction of EMT by cigarette smoke carcinogens in lung epithelial and
non-small-cell lung cancer cells [70]. Overall, these recent reports on the essential role of TCTP in EMT
generated substantial support for our original observation [77] that decreased cellular levels of TCTP
in cancer cells inhibit tumorigenicity by interfering with migration and invasion.
The capacity of TCTP to regulate diverse pathways, from mTOR and genome integrity to cell
migration, has one common feature: cell survival. This is probably best reflected in tumor biology
by reshaping tumor organisation and stemness [78], the latter being a conserved TCTP function from
developmental biology [92] and tissue maintenance [15] to cancer stem cells [40]. A key aspect of
TCTP function as a survival factor is its interaction with both, the anti-apoptotic and pro-apoptotic
machinery. It was recently discovered that TCTP contains a BH3-domain, which is a common feature
in the Bcl2 family regulators of apoptosis [93]. The crystal structure of a complex of Bcl-xL with a
TCTP11–31 deletion variant revealed that TCTP refolds in a helical conformation upon binding the
BH3-groove of Bcl-xL. Most importantly, TCTP potentiates the anti-apoptotic function of Bcl-xL, which
is a unique feature [93]. On the other hand, TCTP has been shown to interact with the p53 tumor
suppressor [40,78]. TCTP and p53 are involved in a negative reciprocal feedback loop, in which p53
represses the transcription of TCTP and the latter promotes the degradation of p53 [40]. This negative
feedback loop is important for cell fate.
A study in hepatocellular cancer revealed that TCTP overexpression in this cancer induces mitotic
defects [41], which is in line with other data showing that TCTP is involved in stabilising the mitotic
spindle and is important for orderly mitotic/meiotic progression [94]. Our data also indicate that normal
breast stem cells and cancer stem cells have an increased expression of TCTP [40]. As in developmental
biology, stemness has to be protected from cell death. Importantly, we observed that breast cancer
patients expressing high levels of TCTP in their tumors have a high grade, aggressive malignancy
with a poor prognosis [40]. Similar observations have since been published for hepatocellular cancer
(HCC) [41], colorectal cancer (CRC) [95], as well as for lung [90], breast [96], and gallbladder [97]
cancer. Such elevated levels of TCTP in aggressive malignant disease may contribute to yet another
problem, i.e., the enhanced resistance to various treatment modalities. For breast [98], lung [99],
and colorectal [100] cancer cells, it has been shown that increased TCTP levels contribute to an increase
in radio- and/or chemo-resistance.
Since the beginning of our research, it was obvious that TCTP is a potentially important target
for cancer treatment. Sertraline and thioridazine are able to neutralise TCTP and hence, decrease its
expression, which leads to apoptosis of cancer cells [79]. Sertraline is now being tested in phase I/II
clinical studies [101]. Recently, it was demonstrated that TCTP is a promising target in melanoma, also
using sertraline as a drug [102]. In our initial experiments targeting TCTP, we employed anti-histaminic
drugs [79]. It has since been shown that anti-histaminic drugs interact with TCTP, and they were
suggested as an approach to differentiation therapy [103]. The finding that the anti-malarial drug
dihydroartemisinin (DHA), which also has anti-cancer activity [104], binds to and promotes the
degradation of human TCTP (fortilin) [74], prompted initial studies to test the use of artemisinin
derivatives against TCTP, either alone in gallbladder cancer [97] or in combination therapy against
breast cancer [96,105]. Yet another approach, i.e., TCTP-antisense oligonucleotides, is being explored
as a strategy against prostate cancer, and this seems to show some promise [106].
4.2. TCTP in Cardiovascular and Metabolic Diseases
Apart from cancer, TCTP dysregulation is also involved in a range of other disease processes
(reviewed in [5,107]; for a compilation see Table 3 below). In a recent study, Cai and colleagues
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reported that TCTP plays a pivotal role in cardiomyocyte survival [46]. Downregulation of
TCTP in cardiomyocytes induced cell death with apoptotic and autophagic features. Conversely,
cardiomyocyte-specific overexpression of TCTP in mice resulted in decreased susceptibility to
doxorubicin-induced cardiac dysfunction. In this case, TCTP acted as a disease-preventing factor.
However, in the case of atherosclerosis, two earlier publications demonstrated that TCTP promotes the
disease, albeit through two quite different mechanisms. Pinkaew et al. studied the effect of heterozygous
deficiency of TCTP (fortilin) in mice, in a background of hypercholesteraemia [108]. They arrived at
the conclusion that TCTP prevents apoptosis and therefore the reduction of macrophages, which are
main contributors to the development of atherosclerosis. Kyunglim Lee’s group had previously shown
that TCTP overexpression resulted in the inhibition of the Na,K-ATPase, and in the development of
systemic hypertension in mice as early as six weeks after birth [109]. In a later paper, they demonstrated
that, in ApoE-knockout mice, TCTP overexpression and consequently hypertension accelerated the
development of atherosclerotic lesions caused by high-fat and high-cholesterol diet [110].
In a recent review article, K. Lee’s group summarised the consequences of the inhibition of the
Na,K-ATPase by TCTP. Apart from the development of systemic hypertension, there are additional
clinically relevant consequences, i.e., an increased tendency to form lens cataracts in mice and the
activation of tumorigenic signalling pathways [111]. Another cardiovascular disease, in which a direct
involvement of TCTP has been documented, is pulmonary arterial hypertension (PAH), a lethal disease
caused by excessive proliferation of pulmonary endothelial cells (ECs). Using a proteomic approach,
Lavoie et al. identified TCTP as one of 22 proteins that are significantly altered in the blood outgrowth
ECs (BOECs) of patients with hereditary PAH [112]. Immunostaining revealed a marked increase in
TCTP levels particularly in complex lesions of lungs from PAH patients, as well as in a rat model of
severe and irreversible PAH. TCTP-knockdown led to an increase in apoptosis and to a reduction
of the hyperproliferative phenotype in BOECs from PAH patients. In a recent follow-up study, the
group also observed that silencing of TCTP in such BOECs resulted in significant alterations of the
morphology and the migration behaviour of these cells [113]. They also demonstrated that TCTP can
be transferred from ECs to pulmonary artery smooth muscle cells via exosomes, and in this way, the
protein transfers the proliferative phenotype and apoptosis resistance onto neighbouring cell layers,
thus playing a core role in the pathobiology of the disease.
Since TCTP is a cytoprotective protein involved in maintaining the cellular homeostasis of
specialised cell types, its dysregulation may also play a role in metabolic disease states, such as diabetes.
We found that in pancreatic β-cells, TCTP levels are regulated by glucose and that TCTP participates
in protecting these cells against apoptosis induced by fatty acids [114]. In a more detailed study,
Tsai et al. investigated the adaptation of β-cell mass in mice, both during early development and in
insulin-resistant states, and found that TCTP expression correlated with phases of β-cell proliferation
and mass expansion [115]. Specific knockout of TCTP in β-cells resulted in decreased growth signalling,
β-cell proliferation and mass development, eventually leading to reduced insulin production and
hyperglycemia. These observations received additional support by the recent finding that in mouse
pancreatic islets, TCTP expression is regulated by the insulin-response element binding protein-1
(IRE-BP1) [31].
One of the pathologies associated with diabetes is nephrotic podocyte hypertrophy, which leads to
an increase of glomeruli and to proteinuria. Kim et al. used a mouse model to study the involvement
of TCTP in the development of this condition [116]. They found that TCTP knockdown reduced the
activation of mTORC1 downstream effectors, the overproduction of cyclin-dependent kinases, as
well as the size of podocytes and the glomeruli. In db/db mice, knockdown of TCTP prevented the
development of diabetic nephropathy. Another type of hypertrophy, not related to diabetes, where
TCTP overexpression was shown to be involved, is skeletal muscle hypertrophy. An in-depth study by
Goodman and colleagues elucidated several aspects of TCTP’s role and regulation in skeletal muscle,
using a range of mouse models [61]. They showed that TCTP is translationally up-regulated via the
mTORC1 signalling pathway in skeletal muscle, under both hypertrophic and atrophic conditions.
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TCTP was sufficient to induce muscle fiber hypertrophy, and the protein may also be involved in
inhibiting protein degradation.
Taken together, the various examples of diseases involving TCTP dysregulation (Table 3 below)
show that, depending on the specific setting or cell type, the role of TCTP can be either in preventing or
in promoting disease processes. TCTP as a cytoprotective protein may be involved in preventing the
development of disease, as we see in model studies for cardiomyocytes [46] or pancreatic β-cells [115].
The properties of TCTP as a growth promoting and anti-apoptotic protein can also exacerbate
disease processes, e.g., by driving cells into a hyperproliferative state, as in cancer (Section 4.1),
PAH [112,113], diabetic nephropathy [116], or muscle hypertrophy [61], by preventing apoptosis,
as shown for atherosclerosis [108] and PAH [112,113] or by inhibiting Na,K-ATPase, which leads to
hypertension [111].
4.3. Allergic and Immune Disorders—TCTP as Histamine Releasing Factor
The discovery of the activity of TCTP as a histamine-releasing factor (HRF) has spurred a
considerable research effort aimed at delineating its specific role in triggering cellular responses
associated with allergic and other immune disorders. Various aspects of this work were reviewed
on earlier occasions [5,57,117,118]; however, since then considerable progress has been made in
understanding certain details of the role of TCTP/HRF in the development of various allergic disorders.
These recent developments are summarised in a review by T. Kawakami and colleagues in this Special
Issue in Cells [56], and for further details, the reader is referred to this article. Here, we will just
mention a few core points: 1. After some initial controversy about the IgE-binding activity of HRF,
it has been clarified that HRF binds to a subset of IgE molecules, in this way triggering histamine
release [117]. 2. Several lines of evidence show that it is the dimer of TCTP/HRF, which is the active
form for its extracellular activity [118]. The structure of the TCTP dimer has been solved and a model
for dimerisation and the IgE binding site was derived from this [119]. A more recent paper also implied
the flexible loop of the TCTP/HRF dimer in the activity of the molecule in triggering cytokine release
from BEAS2B cells [120]. 3. The role and involvement of HRF in the following allergic disease states
has been elucidated, at least in part, either in mouse models or in limited investigations in patients
(Table 3): Asthma (reviewed in [56,117,118]), atopic dermatitis [121], food allergy [122,123], and chronic
urticaria [124,125]. 4. A number of peptide and other inhibitors of TCTP/HRF showed some promise
in alleviating symptoms elicited by this molecule in the context of allergic diseases [56].
Table 3. Dysregulation of TCTP in disease processes.
Type of Disease

Examples

Function of TCTP

References

Cancer

Drosophila; HCC
Drosophila; human cells
Breast cancer
Various cancer cells
Breast cancer
Lung cancer, melanoma
Melanoma, gallbladder, CRC
Breast, lung, CRC cells

TOR pathway; cell cycle progr.
DNA repair/genome stability
Antagonism to p53
Anti-apoptotic activity
Maintaining cancer stem cells
Promoting EMT
Involvement in metastasis
Radio- and chemoresistance

[41,81,82]
[83,84,86]
[40,78]
[40,78,93]
[40,78]
[70,88–91]
[88,95,97]
[98–100]

Cardiovascular
and metabolic
diseases

Heart failure
Atherosclerosis

Protection of cardiomyocytes
- apoptosis in macrophages
- causing hypertension

[46]
[108]
[110]

Hypertension, cataracts
Pulmonary arterial
hypertension (PAH)

Inhibition of Na,K-ATPase
Proliferation, anti-apoptosis
in epithelial/endothelial cells

[109,111]
[112,113]

Hyperglycemia, diabetes
Diabetic nephropathy
Muscle hypertrophy

Protects pancreatic β-cells
Promotes podocyte growth
Increase of TCTP and mTORC1

[114,115]
[116]
[61]

Asthma
Atopic dermatitis
Food allergy
Chronic urticaria

Dimeric HRF/TCTP binds to
IgE+ on mast cells/basophils
and triggers histamine
and cytokine release

[56,117,118]
[121]
[122,123]
[124,125]

Allergic
and immune
disorders
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Another paper published in this Special Issue of Cells reported quite a different aspect of TCTP’s
involvement in inflammatory responses. The group of A. Senff-Ribeiro in Brazil had previously found
that TCTP is part of the venom from the Brown Spider Loxosceles intermedia. They have now shown
that TCTP is a synergistic factor contributing to the exacerbated inflammatory response elicited by the
main toxin of the venom [126].
5. Synopsis
Recent years have seen a considerable deepening of our insight into the multiple biological
functions of TCTP/fortilin/HRF, into the mechanisms of its regulation and into how dysregulation of the
protein may contribute to various disease processes. At the cellular level, we learned more about the
role of TCTP in the cell division process, both mitotic and meiotic; its function in stabilising polar spindle
microtubules and the importance of the mitotic phosphorylation of TCTP by Plk1 for its detachment
from the spindle. A novel mechanism for cell cycle control by TCTP was recently discovered in plants
and insects. TCTP interacts with the CSN4 subunit of the COP9 signalosome complex to regulate cell
cycle progression at the G1/S transition, through modification of the activity of Cullin–Ring ubiquitin
ligases. This is important in both cell proliferation and organ development; however, the relevance
of deregulation by this mechanism in diseases is yet to be documented. The importance of TCTP in
organ development was further confirmed by additional examples in insects (tissue regeneration),
in vertebrates (nervous system development) and in plants (lateral root formation).
The association of TCTP with the protein synthesis machinery was further consolidated by the
discovery of its interaction with the additional ribosomal factors, EF1A2 and RACK1, as well as with
mRNAs. Detailed structural studies confirmed that the previously reported binding of TCTP to EF1B
is the most conserved interaction of TCTP. However, it is still an open question, whether TCTP affects
protein synthesis rates generally, and/or modulates the translation of specific mRNAs. We certainly
know several examples of TCTP regulating the stability of individual proteins.
The function of TCTP as a cytoprotective protein is well established, and several additional
examples have now been reported. As a new mechanism, the involvement of TCTP in the unfolded
protein response to prevent ER-stress was recently revealed. Autophagy is another important
cell-homeostatic mechanism, and a few papers described the involvement of TCTP in this process as
well, although the precise effect of TCTP on autophagy is still a matter of debate.
Cellular TCTP levels are highly regulated in response to alterations of a variety of cell physiologic
conditions. We learned more about regulatory mechanisms that are involved in modulating TCTP
levels. The list of transcription factors regulating TCTP mRNA synthesis has been extended by the
tumor suppressor protein p53 and by IRE-BP1, an insulin-responsive transcription factor. We now
know several translational control mechanisms, which may modulate the translational efficiency of
TCTP mRNA; these are (1) signalling through the mTORC1 pathway, e.g., during growth induction of
TCTP synthesis, (2) negative regulation by PKR in stress conditions, (3) mRNA stability regulation in
Trypanosomes and (4) regulation through a small number of microRNAs in cancer. Several examples
were reported, showing that TCTP levels may be modulated through regulated protein degradation.
In serum starvation, TCTP was found to be degraded through chaperone-mediated autophagy.
The involvement of TCTP in cancer has been repeatedly proven. More examples of high TCTP
levels being associated with a poor outcome in cancer patients have been reported. The participation
of TCTP in the following cancer-promoting pathways has been demonstrated: the mTOR pathway and
cell cycle progression, DNA repair and genome stability, antagonism to tumor suppressor p53 and
anti-apoptotic activity, maintenance of ‘stemness’ in cancer cells, promotion of EMT and involvement
in metastasis, and development of radio- and chemoresistance in cancer cells. Initial ideas to target
TCTP as (part of) potential anti-cancer strategies have been published. Other disease processes, where
dysregulation of TCTP might be a contributing factor, include cardiovascular diseases (arthrosclerosis
and hypertension) and metabolic disorders (diabetes, muscle hypertrophy). The extracellular function
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of dimerised TCTP as histamine-releasing factor (HRF) in allergic and immune disorders has been
further clarified, for asthma, atopic dermatitis, food allergy, and chronic urticaria.
With this extended knowledge about the principal functions of TCTP/fortilin/HRF in many
biological and disease processes, our ‘toolbox’ should be large enough now for taking first steps
towards ‘translating’ this knowledge into practical medical applications.
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